TIDAL: Target-Induced Droplet Assembly of Ligands

Los Alamos National Laboratory is offering its TIDAL technology—a protein‑only, phase‑separation platform that uses engineered nanobodies to form target‑induced liquid droplets. The platform can be licensed for multiple applications, including cost‑effective protein purification, injectable slow‑release therapeutics, intracellular protein sequestration, and high‑sensitivity diagnostics. Interested parties may submit proposals by the stated deadline to explore exclusive or non‑exclusive licensing arrangements. • Enables resin‑free protein purification, reducing manufacturing costs. • Provides a programmable delivery system that can transition from liquid injection to solid depot. • Supports intracellular targeting of disease‑driving proteins and enhanced diagnostic assays. • Technology is at TRL 3, with a pending U.S. patent (LA‑UR‑26‑27937).